Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 18.43 USD 0.16% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Travere Therapeutics Inc?
Write Note

Wall Street
Price Targets

TVTX Price Targets Summary
Travere Therapeutics Inc

Wall Street analysts forecast TVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TVTX is 27.48 USD with a low forecast of 15.15 USD and a high forecast of 44.1 USD.

Lowest
Price Target
15.15 USD
18% Downside
Average
Price Target
27.48 USD
49% Upside
Highest
Price Target
44.1 USD
139% Upside

TVTX Last Price Targets
Travere Therapeutics Inc

The latest public price target was made on Oct 31, 2024 by Liisa Bayko from Evercore ISI , who expects TVTX stock to rise by 79% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Liisa Bayko
Evercore ISI
33 USD
Upside 79%
3 weeks ago
Oct 31, 2024
Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI
StreetInsider
Mohit Bansal
Wells Fargo
27 USD
Upside 47%
1 month ago
Oct 21, 2024
Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight
StreetInsider
Liisa Bayko
Evercore ISI
30 USD
Upside 63%
1 month ago
Oct 10, 2024
Travere Therapeutics price target raised to $30 from $12 at Evercore ISI
TheFly
Jason Zemansky
Bank of America Securities
20 USD
Upside 9%
1 month ago
Oct 9, 2024
Travere Therapeutics price target raised to $20 from $18 at BofA
TheFly
Carter Gould
Barclays
18 USD
Downside 2%
1 month ago
Oct 1, 2024
Travere Therapeutics price target raised to $18 from $14 at Barclays
TheFly
Greg Harrison
Bank of America Securities
18 USD
Downside 2%
1 month ago
Sep 27, 2024
Travere Therapeutics (TVTX) PT Lowered to $18 at BofA Securities
StreetInsider
Ed Arce
H.C. Wainwright
18 USD
Downside 2%
1 month ago
Sep 27, 2024
Travere Therapeutics price target lowered to $18 from $23 at H.C. Wainwright
TheFly
Vamil Divan
Guggenheim
23 USD
Upside 25%
1 month ago
Sep 27, 2024
Travere Therapeutics price target lowered to $23 from $25 at Guggenheim
TheFly
Ed Nash
Canaccord Genuity
23 USD
Upside 25%
2 months ago
Sep 10, 2024
Travere Therapeutics (TVTX) PT Raised to $23 at Canaccord Genuity
StreetInsider
Vamil Divan
Guggenheim
25 USD
Upside 36%
2 months ago
Sep 9, 2024
Guggenheim Upgrades Travere Therapeutics (TVTX) to Buy
StreetInsider
Nicole Gabreski
Piper Sandler
12 USD
Downside 35%
2 months ago
Aug 28, 2024
Piper Sandler Reiterates Neutral Rating on Travere Therapeutics (TVTX)
StreetInsider
Ed Arce
H.C. Wainwright
20 USD
Upside 9%
3 months ago
Aug 2, 2024
Travere Therapeutics price target raised to $20 from $19 at H.C. Wainwright
TheFly
Ed Nash
Canaccord Genuity
18 USD
Downside 2%
6 months ago
May 7, 2024
Travere Therapeutics (TVTX) PT Raised to $18 at Canaccord Genuity
StreetInsider
Ed Arce
H.C. Wainwright
19 USD
Upside 3%
6 months ago
Apr 24, 2024
Travere Therapeutics price target raised to $19 from $17 at H.C. Wainwright
TheFly
Show More Price Targets
Show Less Price Targets
Liisa Bayko
Evercore ISI
Price Target 33 USD
Upside/Downside 79%
View Source
Mohit Bansal
Wells Fargo
Price Target 27 USD
Upside/Downside 47%
View Source
Liisa Bayko
Evercore ISI
Price Target 30 USD
Upside/Downside 63%
View Source
Jason Zemansky
Bank of America Securities
Price Target 20 USD
Upside/Downside 9%
View Source
Carter Gould
Barclays
Price Target 18 USD
Upside/Downside 2%
View Source
Greg Harrison
Bank of America Securities
Price Target 18 USD
Upside/Downside 2%
View Source
Ed Arce
H.C. Wainwright
Price Target 18 USD
Upside/Downside 2%
View Source
Vamil Divan
Guggenheim
Price Target 23 USD
Upside/Downside 25%
View Source
Ed Nash
Canaccord Genuity
Price Target 23 USD
Upside/Downside 25%
View Source
Vamil Divan
Guggenheim
Price Target 25 USD
Upside/Downside 36%
View Source
Nicole Gabreski
Piper Sandler
Price Target 12 USD
Upside/Downside 35%
View Source
Ed Arce
H.C. Wainwright
Price Target 20 USD
Upside/Downside 9%
View Source
Ed Nash
Canaccord Genuity
Price Target 18 USD
Upside/Downside 2%
View Source
Ed Arce
H.C. Wainwright
Price Target 19 USD
Upside/Downside 3%
View Source
Show More Price Targets
Show Less Price Targets
Travere Therapeutics Inc Competitors:
Price Targets
688373
Shanghai MicuRx Pharmaceutical Co Ltd
39% Upside
301301
Yili Chuanning Biotechnology Co Ltd
17% Downside
TNGX
Tango Therapeutics Inc
200% Upside
DAWN
Day One Biopharmaceuticals Inc
172% Upside
CRVO
Diffusion Pharmaceuticals Inc
513% Upside
CDTX
Cidara Therapeutics Inc
60% Upside
STRO
Sutro Biopharma Inc
376% Upside
9926
Akeso Inc
3% Upside

Revenue
Forecast

Revenue Estimate
Travere Therapeutics Inc

For the last 8 years the compound annual growth rate for Travere Therapeutics Inc's revenue is 5%. The projected CAGR for the next 3 years is 53%.

5%
Past Growth
53%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TVTX's stock price target?
Price Target
27.48 USD

According to Wall Street analysts, the average 1-year price target for TVTX is 27.48 USD with a low forecast of 15.15 USD and a high forecast of 44.1 USD.

What is Travere Therapeutics Inc's Revenue forecast?
Projected CAGR
53%

For the last 8 years the compound annual growth rate for Travere Therapeutics Inc's revenue is 5%. The projected CAGR for the next 3 years is 53%.

Back to Top